MX2020005398A - Compuestos para el tratamiento de trastornos neuromusculares. - Google Patents
Compuestos para el tratamiento de trastornos neuromusculares.Info
- Publication number
- MX2020005398A MX2020005398A MX2020005398A MX2020005398A MX2020005398A MX 2020005398 A MX2020005398 A MX 2020005398A MX 2020005398 A MX2020005398 A MX 2020005398A MX 2020005398 A MX2020005398 A MX 2020005398A MX 2020005398 A MX2020005398 A MX 2020005398A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- neuromuscular disorders
- phenoxy acids
- phenoxy
- acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/14—Acetic acid esters of monohydroxylic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a compuestos adecuados para tratar, mejorar y/o prevenir trastornos neuromusculares, incluyendo la reversión del bloqueo neuromuscular inducido por fármacos. Los compuestos como se definen en el presente documento inhiben preferiblemente el canal iónico ClC-1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762598940P | 2017-12-14 | 2017-12-14 | |
EP18151605 | 2018-01-15 | ||
PCT/EP2018/084980 WO2019115777A1 (en) | 2017-12-14 | 2018-12-14 | Phenoxy acids for the treatment of neuromuscular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020005398A true MX2020005398A (es) | 2020-08-17 |
Family
ID=64661403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005398A MX2020005398A (es) | 2017-12-14 | 2018-12-14 | Compuestos para el tratamiento de trastornos neuromusculares. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3723745B1 (es) |
JP (1) | JP2021506813A (es) |
KR (1) | KR20200099146A (es) |
CN (1) | CN111587109A (es) |
AU (1) | AU2018382597B2 (es) |
CA (1) | CA3085226A1 (es) |
IL (1) | IL274744B2 (es) |
MX (1) | MX2020005398A (es) |
SG (1) | SG11202005359TA (es) |
TW (1) | TWI794369B (es) |
WO (1) | WO2019115777A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024121129A1 (en) * | 2022-12-05 | 2024-06-13 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
WO2024121130A1 (en) | 2022-12-05 | 2024-06-13 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1586463A (en) | 1976-08-02 | 1981-03-18 | Shell Int Research | Herbicidal compositions |
KR100552133B1 (ko) * | 2002-06-26 | 2006-02-14 | 한국화학연구원 | 광학활성 (r)-아릴옥시 프로피온산 에스터 유도체의제조방법 |
SE0301009D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
GB0409921D0 (en) | 2004-05-04 | 2004-06-09 | Novartis Ag | Organic compounds |
GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
CA2713864A1 (en) * | 2008-02-04 | 2009-08-13 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
US8999974B2 (en) | 2010-08-09 | 2015-04-07 | Raqualia Pharma Inc. | Acyl piperazine derivatives as TTX-S blockers |
US10934244B2 (en) * | 2015-06-15 | 2021-03-02 | Nmd Pharma A/S | Compounds for use in treating neuromuscular disorders |
TW201720437A (zh) * | 2015-10-29 | 2017-06-16 | Tohoku Techno Arch Co Ltd | 肌萎縮性疾病治療劑 |
-
2018
- 2018-12-13 TW TW107145015A patent/TWI794369B/zh active
- 2018-12-14 EP EP18815729.1A patent/EP3723745B1/en active Active
- 2018-12-14 AU AU2018382597A patent/AU2018382597B2/en active Active
- 2018-12-14 KR KR1020207017872A patent/KR20200099146A/ko not_active Application Discontinuation
- 2018-12-14 CN CN201880080205.1A patent/CN111587109A/zh active Pending
- 2018-12-14 JP JP2020532801A patent/JP2021506813A/ja active Pending
- 2018-12-14 MX MX2020005398A patent/MX2020005398A/es unknown
- 2018-12-14 WO PCT/EP2018/084980 patent/WO2019115777A1/en unknown
- 2018-12-14 SG SG11202005359TA patent/SG11202005359TA/en unknown
- 2018-12-14 CA CA3085226A patent/CA3085226A1/en active Pending
-
2020
- 2020-05-18 IL IL274744A patent/IL274744B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3723745B1 (en) | 2024-06-19 |
EP3723745A1 (en) | 2020-10-21 |
IL274744A (en) | 2020-07-30 |
KR20200099146A (ko) | 2020-08-21 |
SG11202005359TA (en) | 2020-07-29 |
CA3085226A1 (en) | 2019-06-20 |
AU2018382597A1 (en) | 2020-07-02 |
IL274744B2 (en) | 2023-02-01 |
IL274744B (en) | 2022-10-01 |
AU2018382597B2 (en) | 2024-04-04 |
TW201938525A (zh) | 2019-10-01 |
TWI794369B (zh) | 2023-03-01 |
WO2019115777A1 (en) | 2019-06-20 |
JP2021506813A (ja) | 2021-02-22 |
CN111587109A (zh) | 2020-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017016424A (es) | Compuestos para su uso en el tratamiento de trastornos neuromusculares. | |
PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
MX2019012818A (es) | Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. | |
PH12017500829A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
MX2020005545A (es) | Compuestos para el tratamiento de trastornos neuromusculares. | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX2017012730A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer. | |
EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
MX2018012655A (es) | Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. | |
EP3598980A3 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
PH12018502337A1 (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
MY195743A (en) | Isoxazole Hydroxamic Acid Compounds as LPXC Inhibitors | |
MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
PH12020550023A1 (en) | Compositions for treating stress-related disorders | |
MX2017017171A (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
MX2020005398A (es) | Compuestos para el tratamiento de trastornos neuromusculares. | |
WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
MX2019006940A (es) | Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar. | |
MX2020005471A (es) | Compuestos para el tratamiento de trastornos neuromusculares. | |
SA521431094B1 (ar) | مركبات علاج الاضطرابات العصبية والعضلية |